Sotera Health Eyes 3.3% Q4 Revenue Growth After Q3’s $311M Beat
Sotera Health posted Q3 revenues of $311.3 million, a 9.1% year-over-year gain that beat analysts’ expectations and lifted full-year EPS guidance. For Q4, revenue is projected to rise 3.3% versus last year’s 6.5% decline, with analysts maintaining estimates ahead of Tuesday’s results.
1. Q3 Performance Highlights
Sotera Health delivered Q3 revenue of $311.3 million, marking a 9.1% year-over-year increase that surpassed consensus estimates. The strong top-line performance coincided with an unexpected beat on full-year EPS guidance, underscoring operational momentum heading into year end.
2. Q4 Revenue Outlook
Analysts forecast Q4 revenue growth of 3.3% year-over-year, reversing a 6.5% decline in the same quarter last year. Estimate revisions have been minimal over the past month, suggesting confidence in stable demand and pricing for the company’s sterilization and lab services.
3. Peer Comparisons and Analyst Sentiment
In the research tools & consumables segment, Bio-Techne reported flat revenue with a 2% beat while Revvity grew 5.8% topping estimates by 1.1%. The peer group’s average share price slid 3.4% over the past month versus Sotera’s 5.9% decline, with an average analyst price target of $20.44 reflecting optimism ahead of results.